Cullinan Associates Inc. Sells 8,775 Shares of Bristol Myers Squibb Company $BMY

Cullinan Associates Inc. lowered its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 17.2% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 42,219 shares of the biopharmaceutical company’s stock after selling 8,775 shares during the period. Cullinan Associates Inc.’s holdings in Bristol Myers Squibb were worth $2,561,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Citizens Financial Group Inc. RI increased its position in shares of Bristol Myers Squibb by 53.6% during the first quarter. Citizens Financial Group Inc. RI now owns 80,552 shares of the biopharmaceutical company’s stock valued at $4,885,000 after purchasing an additional 28,098 shares during the period. Sovran Advisors LLC boosted its stake in Bristol Myers Squibb by 53.7% during the first quarter. Sovran Advisors LLC now owns 8,724 shares of the biopharmaceutical company’s stock worth $529,000 after buying an additional 3,047 shares in the last quarter. American Trust bought a new stake in Bristol Myers Squibb in the 1st quarter valued at $346,000. WealthShield Partners LLC raised its stake in shares of Bristol Myers Squibb by 6.0% in the 1st quarter. WealthShield Partners LLC now owns 11,565 shares of the biopharmaceutical company’s stock valued at $701,000 after buying an additional 658 shares in the last quarter. Finally, Simplicity Wealth LLC lifted its holdings in shares of Bristol Myers Squibb by 25.5% during the 1st quarter. Simplicity Wealth LLC now owns 11,504 shares of the biopharmaceutical company’s stock worth $698,000 after acquiring an additional 2,340 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently issued reports on BMY. Weiss Ratings reissued a “hold (c+)” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 2nd. UBS Group reiterated a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. HSBC raised their target price on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research report on Tuesday, March 17th. Bank of America decreased their price target on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. Eight research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $61.25.

Bristol Myers Squibb Price Performance

Shares of BMY stock traded down $0.41 during trading hours on Friday, reaching $57.53. 11,202,444 shares of the company were exchanged, compared to its average volume of 12,071,738. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. The stock’s fifty day moving average is $56.83 and its two-hundred day moving average is $57.62. The company has a market cap of $117.49 billion, a price-to-earnings ratio of 16.16, a P/E/G ratio of 0.16 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. During the same quarter in the previous year, the company posted $1.80 EPS. Bristol Myers Squibb’s revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Sell-side analysts forecast that Bristol Myers Squibb Company will post 6.32 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.4%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is 70.79%.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bank of America lowered its price target slightly to $66 from $67 but kept a Buy rating, signaling continued upside potential for Bristol Myers Squibb. Benzinga
• Positive Sentiment: Bristol Myers Squibb’s addition to defensive and value-defensive Russell indices could broaden demand from index-tracking and conservative institutional investors. Yahoo Finance
• Positive Sentiment: The company’s QUILS lung cancer detection program is expanding into new states, reinforcing its reputation in oncology and public-health initiatives. Yahoo Finance

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.